{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:32:28Z","timestamp":1790127148933,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["annemergmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.annemergmed.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:20:00Z","timestamp":1755498000000},"page":"229-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Major Adverse Events With Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0271-6430","authenticated-orcid":false,"given":"Kiril","family":"Dimitrov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Merkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marketa","family":"Dimitrov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svatava","family":"Merkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2025.07.005_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hon.2595","article-title":"Managing the toxicities of CAR T-cell therapy","volume":"37","author":"Neelapu","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1219289","article-title":"Risk factors and outcome of chimeric antigen receptor T-cell patients admitted to pediatric intensive care unit: CART-PICU study","volume":"14","author":"Caballero-Bell\u00f3n","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib9","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib10","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib11","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.3390\/cancers15245746","article-title":"The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: a systematic literature review","volume":"15","author":"Hansen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib13","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2019.12.093","volume":"26","author":"Bachier","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijp.ijp_531_20","article-title":"Chimeric antigen receptor T cell: a cancer immunotherapy","volume":"54","author":"Singh","year":"2022","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib16","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.medin.2019.01.009","article-title":"Cytokine release syndrome. Reviewing a new entity in the intensive care unit","volume":"43","author":"Garc\u00eda Roche","year":"2019","journal-title":"Med Intensiva"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib19","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib20","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"New Eng J Med"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib21","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.bbmt.2019.01.001","article-title":"Harmonizing immune effector toxicity reporting","volume":"25","author":"Heslop","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.634445","article-title":"Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis?","volume":"11","author":"Brown","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib23","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2024.2381989","article-title":"Procalcitonin level threshold and antibiotic use in patients receiving chimeric antigen receptor T-cell therapy","volume":"29","author":"Ramesh","year":"2024","journal-title":"Hematology"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib27","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib29","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/WCO.0000000000000686","article-title":"Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy","volume":"32","author":"Perrinjaquet","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib30","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biologic correlates of neurotoxicity associated with CAR T cell therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL)","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric antigen receptor T cell-related neurotoxicity: mechanisms, clinical presentation, and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib32","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2023011669","article-title":"Impact of diagnostic investigations in the management of CAR T-cell\u2013associated neurotoxicity","volume":"8","author":"Mauget","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Mart\u00edn-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib34","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib35","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.annemergmed.2019.07.015","article-title":"Adverse events of novel therapies for hematologic malignancies: what emergency physicians should know","volume":"75","author":"Shah","year":"2020","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib36","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S150524","article-title":"Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy","volume":"15","author":"Riegler","year":"2019","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib38","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1182\/blood-2024-210573","article-title":"Managing CAR T-cell toxicity: impact of steroid prophylaxis on toxicity and outcomes","volume":"144","author":"Upadhyay","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-024-10227-1","article-title":"Evolving strategies for addressing CAR T-cell toxicities","volume":"44","author":"Rankin","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.annemergmed.2025.07.005_bib41","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064425010492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064425010492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:19:50Z","timestamp":1773807590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064425010492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0196064425010492"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2025.07.005","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Major Adverse Events With Chimeric Antigen Receptor T-Cell Therapy: Presentation, Diagnosis, and Resuscitation","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}